Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy

Published:November 28, 2022DOI:


      Background aims

      Chimeric antigen receptor (CAR) T-cell therapy is a breakthrough treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. However, many patients do not achieve remission or relapse after remission. Previous studies have demonstrated that eosinophils have synergistic anti-tumor effects with CD8+T cells and pre-CAR T-eosinophil counts are associated with the efficacy of CAR T cells.


      We retrospectively analyzed the eosinophil counts of patients with diffuse large B-cell lymphoma and found it changed remarkably pre- and post-CAR T-cell therapy.


      Patients who achieved complete remission after CAR T-cell infusion had greater post-CAR T-eosinophil counts than those who did not. Kaplan–Meier curves showed that patients with greater eosinophil counts during the second month after CAR T-cell infusion had superior progression-free survival and overall survival compared with those with lower eosinophil counts.


      For patients who responded to CAR T-cell therapy, eosinophil counts also can be used to predict 6-month duration of response. In conclusion, the post-CAR T-eosinophil count is associated with the prognosis of patients treated with CAR T-cell therapy and can be used to clinically identify patients who can achieve longer remission after CAR T-cell infusion.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nastoupil LJ
        • Jain MD
        • Feng L
        • Spiegel JY
        • Ghobadi A
        • Lin Y
        • et al.
        Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
        J Clin Oncol. 2020; 38: 3119-3128
        • Sermer D
        • Batlevi C
        • Palomba ML
        • Shah G
        • Lin RJ
        • Perales MA
        • et al.
        Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
        Blood Adv. 2020; 4: 4669-4678
        • Neelapu SS
        • Jacobson CA
        • Oluwole OO
        • Munoz J
        • Deol A
        • Miklos DB
        • et al.
        Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
        Blood. 2020; 135: 2106-2109
        • Locke FL
        • Ghobadi A
        • Jacobson CA
        • Miklos DB
        • Lekakis LJ
        • Oluwole OO
        • et al.
        Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial.
        The Lancet Oncology. 2019; : 20
        • Schuster SJ
        • Tam CS
        • Borchmann P
        • Worel N
        • McGuirk JP
        • Holte H
        • et al.
        Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
        Lancet Oncol. 2021; 22: 1403-1415
        • Schuster SJ
        • Bishop MR
        • Tam CS
        • Waller EK
        • Borchmann P
        • McGuirk JP
        • et al.
        Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
        N Engl J Med. 2019; 380: 45-56
        • Di Blasi R
        • Le Gouill S
        • Bachy E
        • Cartron G
        • Beauvais D
        • Le Bras F
        • et al.
        Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis.
        Blood. 2022;
        • Vercellino L
        • Di Blasi R
        • Kanoun S
        • Tessoulin B
        • Rossi C
        • D'Aveni-Piney M
        • et al.
        Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
        Blood Adv. 2020; 4: 5607-5615
        • Al Zaki A
        • Feng L
        • Watson G
        • Ahmed S
        • Mistry H
        • Nastoupil LJ
        • et al.
        Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy.
        Blood Adv. 2022;
        • Shouval R
        • Alarcon Tomas A
        • Fein JA
        • Flynn JR
        • Markovits E
        • Mayer S
        • et al.
        Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
        J Clin Oncol. 2021; Jco2102143
        • Tepper R
        • Coffman R
        • Leder P.
        An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.
        Science (New York, NY). 1992; 257: 548-551
        • Prizment A
        • Vierkant R
        • Smyrk T
        • Tillmans L
        • Lee J
        • Sriramarao P
        • et al.
        Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study.
        Mod Pathol. 2016; 29: 516-527
        • Simon S
        • Hu X
        • Panten J
        • Grees M
        • Renders S
        • Thomas D
        • et al.
        Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.
        Oncoimmunology. 2020; 91727116
        • Mota J
        • Teo M
        • Whiting K
        • Li H
        • Regazzi A
        • Lee C
        • et al.
        Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.
        Journal of immunotherapy (Hagerstown, Md: 1997). 2021;
        • Hude I
        • Sasse S
        • Bröckelmann PJ
        • von Tresckow B
        • Momotow J
        • Engert A
        • et al.
        Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.
        Br J Haematol. 2018; 181: 837-840
        • Carretero R
        • Sektioglu IM
        • Garbi N
        • Salgado OC
        • Beckhove P
        • Hämmerling GJ.
        Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.
        Nature immunology. 2015; 16: 609-617
        • Jia Q
        • Qin D
        • He F
        • Xie Q
        • Ying Z
        • Zhang Y
        • et al.
        Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.
        Theranostics. 2021; 11: 4699-4709
        • Lai W
        • Xie H
        • Liu Y
        • Zheng F
        • Zhang Y
        • Lei Q
        • et al.
        Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors.
        Stem cell reports. 2021; 16: 1697-1704
        • Strati P
        • Varma A
        • Adkins S
        • Nastoupil LJ
        • Westin J
        • Hagemeister FB
        • et al.
        Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
        Haematologica. 2020;
        • Logue JM
        • Zucchetti E
        • Bachmeier CA
        • Krivenko GS
        • Larson V
        • Ninh D
        • et al.
        Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
        Haematologica. 2021; 106: 978-986
        • Sakkal S
        • Miller S
        • Apostolopoulos V
        • Nurgali K.
        Eosinophils in Cancer: Favourable or Unfavourable?.
        Current medicinal chemistry. 2016; 23: 650-666
        • Zhang Y
        • Ren H
        • Wang L
        • Ning Z
        • Zhuang Y
        • Gan J
        • et al.
        Clinical impact of tumor-infiltrating inflammatory cells in primary small cell esophageal carcinoma.
        Int J Mol Sci. 2014; 15: 9718-9734
        • Harbaum L
        • Pollheimer MJ
        • Kornprat P
        • Lindtner RA
        • Bokemeyer C
        • Langner C.
        Peritumoral eosinophils predict recurrence in colorectal cancer.
        Mod Pathol. 2015; 28: 403-413
        • von Wasielewski R
        • Seth S
        • Franklin J
        • Fischer R
        • Hübner K
        • Hansmann ML
        • et al.
        Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors.
        Blood. 2000; 95: 1207-1213
        • van Driel WJ
        • Hogendoorn PC
        • Jansen FW
        • Zwinderman AH
        • Trimbos JB
        • Fleuren GJ.
        Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response.
        Human pathology. 1996; 27: 904-911
        • Rimini M
        • Franco P
        • De Bari B
        • Zampino M
        • Vagge S
        • Frassinetti G
        • et al.
        The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation.
        Cancers. 2021; 13
        • Majzner RG
        • Mackall CL.
        Clinical lessons learned from the first leg of the CAR T cell journey.
        Nat Med. 2019; 25: 1341-1355